On the stock market since 2012, it operates in the world of health and science. It has 7,872 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 6% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $955B would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 35% — still a thick cushion, though costs have been eating into it lately.
There is $981B in the vault; even if every debt were paid off, $955B would remain.
It pays out $1.34 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, CHGCF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CHGCF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.